Somatostatin (SS) is one of several peptides cleaved during the post translational processing of pro-SS. SS and SS-related peptides (SRP) are released by cells in brain, hypothalamus, pancreas and intestine and at least two SRP are known to suppress the secretion of several peptides involved in fuel homeostasis. The overall aim of this proposal is to evaluate the hypothesis that SS28, a product of processing of pro-SS, is preferentially released from the small intestine and, transported to the endocrine pancreas in the circulation, acts as a physiological modulator of postprandial insulin secretion. Four specific questions include: 1) is the small intestine the principal source of circulating SRP?; 2) if so, what are the signals that lead to their secretion?; 3) does SS28 and other precursors exert effects both locally and on distant cells?; and 4) is the secretion of SRP perturbed in and contribute to hormonal changes in pathologic states? These questions will be tested in man, baboon and rat. Measurements of SRP will be made by radioimmunoassay using antisera specific for different regions of pro-SS. These include SS28, SS28(1-12), SS28(1-14), and SS28(15-28), as well as two precursors of SS28 of estimated MW of 12 and 5 K daltons. SRP in the peripheral circulation of normal man will be evaluated in response to oral and IV nutriments, substrates, neurotransmitters, and peptides. The content of SRP and their biosynthetic pathways will be examined in human intestinal mucosa obtained by biopsy. Possible alterations in secretion of SRP in man with metabolic and intestinal disorders will be evaluated. Hepatic clearance of SRP will be examined in the baboon. The release of SRP into the venous and luminal effluent in the in situ perfused rat small intestine will be evaluated to determine if different peptides are secreted. To test the hypothesis that circulating SS28 and possibly other SRP influence insulin secretion, passive neutralization experiments with antisera against SRP, and depletion of tissue levels of SRP with cysteamine will be carried out. The long-term objective is to determine if SRP release during nutriment absorption act to restrain postprandial events in fuel homeostasis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK034397-04
Application #
3232729
Study Section
Metabolism Study Section (MET)
Project Start
1984-09-01
Project End
1989-08-31
Budget Start
1987-09-01
Budget End
1988-08-31
Support Year
4
Fiscal Year
1987
Total Cost
Indirect Cost
Name
University of Washington
Department
Type
Schools of Medicine
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Elder, Deborah A; Prigeon, Ronald L; Wadwa, R Paul et al. (2006) Beta-cell function, insulin sensitivity, and glucose tolerance in obese diabetic and nondiabetic adolescents and young adults. J Clin Endocrinol Metab 91:185-91
Quddusi, Shaista; Vahl, Torsten P; Hanson, Kevin et al. (2003) Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans. Diabetes Care 26:791-8
Prigeon, Ronald L; Quddusi, Shaista; Paty, Breay et al. (2003) Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect. Am J Physiol Endocrinol Metab 285:E701-7
Ensinck, John W; Laschansky, Ellen C; Vogel, Robin E et al. (2003) Effect of ingested nutrients on the release of thrittene into the human circulation. J Clin Endocrinol Metab 88:4798-804
Ensinck, John W; Baskin, Denis G; Vahl, Torsten P et al. (2002) Thrittene, homologous with somatostatin-28((1-13)), is a novel peptide in mammalian gut and circulation. Endocrinology 143:2599-609
D'Alessio, D A; Vogel, R; Prigeon, R et al. (1996) Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. J Clin Invest 97:133-8
D'Alessio, D A; Prigeon, R L; Ensinck, J W (1995) Enteral enhancement of glucose disposition by both insulin-dependent and insulin-independent processes. A physiological role of glucagon-like peptide I. Diabetes 44:1433-7
Burckhardt, B; Delco, F; Ensinck, J W et al. (1994) Cholecystokinin is a physiological regulator of gastric acid secretion in man. Eur J Clin Invest 24:370-6
D'Alessio, D A; Kahn, S E; Leusner, C R et al. (1994) Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 93:2263-6
Hildebrand, P; Ensinck, J W; Ketterer, S et al. (1991) Effect of a cholecystokinin antagonist on meal-stimulated insulin and pancreatic polypeptide release in humans. J Clin Endocrinol Metab 72:1123-9

Showing the most recent 10 out of 15 publications